IN8BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
IN8BIO, INC. (INAB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.08 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 593.16K shares.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 490.50K shares, a 82.74% decline year-over-year.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 107.33K shares, a 98.32% decline from fiscal 2024.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 6.39M shares, a 113.15% increase from fiscal 2023.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 3.00M shares, a 62.38% increase from fiscal 2022.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.85M shares, a 49.82% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 593.16K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 1.08M shares 10-Q · filed 2026-08-06 | 1.08M shares derived: sum of 3 quarters · filed 2026-08-06 | 1.08M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 490.50K shares 10-Q · filed 2026-05-07 | 490.50K shares derived: sum of 2 quarters · filed 2026-05-07 | 490.50K shares derived: sum of 3 quarters · filed 2026-05-07 | -2.24M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-12 | -2.73M shares derived: sum of 3 quarters · filed 2026-03-12 | 107.33K shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -2.73M shares derived: sum of 2 quarters · filed 2025-11-06 | 107.33K shares 10-Q · filed 2025-11-06 | 2.52M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | -2.73M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 107.33K shares 10-Q · filed 2025-08-07 | 2.52M shares derived: sum of 3 quarters · filed 2025-08-07 | 4.31M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 2.84M shares 10-Q · filed 2025-05-07 | 5.25M shares derived: sum of 2 quarters · filed 2025-05-07 | 7.04M shares derived: sum of 3 quarters · filed 2025-05-07 | 7.54M shares derived: sum of 4 quarters · filed 2025-05-07 |
| 2024-12-31 | 2.41M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 4.20M shares derived: sum of 2 quarters · filed 2025-03-13 | 4.70M shares derived: sum of 3 quarters · filed 2025-03-13 | 6.39M shares 10-K · filed 2025-03-13 |
| 2024-09-30 | 1.79M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 2.29M shares derived: sum of 2 quarters · filed 2024-11-12 | 3.98M shares 10-Q · filed 2024-11-12 | 4.06M shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 494.55K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 2.19M shares 10-Q · filed 2024-08-08 | 2.27M shares derived: sum of 3 quarters · filed 2024-08-08 | 2.27M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 1.69M shares 10-Q · filed 2024-05-09 | 1.77M shares derived: sum of 2 quarters · filed 2024-05-09 | 1.78M shares derived: sum of 3 quarters · filed 2024-05-09 | 4.67M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 81.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 87.15K shares derived: sum of 2 quarters · filed 2024-03-14 | 2.98M shares derived: sum of 3 quarters · filed 2024-03-14 | 3.00M shares 10-K · filed 2024-03-14 |
| 2023-09-30 | 5.35K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 2.89M shares derived: sum of 2 quarters · filed 2023-11-09 | 2.92M shares 10-Q · filed 2023-11-09 | 3.61M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 2.89M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 2.91M shares 10-Q · filed 2023-08-10 | 3.60M shares derived: sum of 3 quarters · filed 2023-08-10 | 3.62M shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 20.75K shares 10-Q · filed 2023-05-12 | 715.23K shares derived: sum of 2 quarters · filed 2023-05-12 | 734.48K shares derived: sum of 3 quarters · filed 2023-05-12 | 1.06M shares derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-12-31 | 694.48K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 713.73K shares derived: sum of 2 quarters · filed 2023-03-30 | 1.04M shares derived: sum of 3 quarters · filed 2023-03-30 | 1.85M shares 10-K · filed 2023-03-30 |
| 2022-09-30 | 19.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 349.60K shares derived: sum of 2 quarters · filed 2022-11-10 | 1.15M shares 10-Q · filed 2022-11-10 | 1.60M shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 330.35K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | 1.13M shares 10-Q · filed 2022-08-12 | 1.58M shares derived: sum of 3 quarters · filed 2022-08-12 | 2.06M shares derived: sum of 4 quarters · filed 2022-08-12 |
| 2022-03-31 | 801.60K shares 10-Q · filed 2022-05-12 | 1.25M shares derived: sum of 2 quarters · filed 2022-05-12 | 1.73M shares derived: sum of 3 quarters · filed 2022-05-12 | |
| 2021-12-31 | 445.56K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 926.83K shares derived: sum of 2 quarters · filed 2022-03-17 | 1.23M shares 10-K · filed 2022-03-17 | |
| 2021-09-30 | 481.27K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 786.41K shares 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | 305.13K shares 10-Q · filed 2021-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |